Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Placebo effect in Obsessive-Compulsive Disorder (OCD). Placebo response and placebo responders in OCD: The trend over time.

Kotzalidis GD, Del Casale A, Simmaco M, Pancheri L, Brugnoli R, Paolini M, Gualtieri I, Ferracuti S, Savoja V, Cuomo I, De Chiara L, Mosca A, Sani G, Girardi P, Pompili M, Rapinesi C, On Behalf Of The Sapienza Group For The Study Of The Placebo Effect In Psychiatric Disorders.

Curr Neuropharmacol. 2018 Oct 26. doi: 10.2174/1570159X16666181026163922. [Epub ahead of print]

PMID:
30370851
2.

Vitamins D and K as Factors Associated with Osteopathy in Chronic Pancreatitis: A Prospective Multicentre Study (P-BONE Study).

Stigliano S, Waldthaler A, Martinez-Moneo E, Lionetto L, Robinson S, Malvik M, Hedstrom A, Kaczka A, Scholdei M, Haas S, Simmaco M, Delle Fave G, Lohr M, Simon P, Capurso G.

Clin Transl Gastroenterol. 2018 Oct 15;9(10):197. doi: 10.1038/s41424-018-0066-8.

3.

Single nucleotide polymorphism of <italic>GSTP1</italic> and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy.

Nicosia L, Gentile G, Reverberi C, Minniti G, Valeriani M, de Sanctis V, Marinelli L, Cipolla F, de Luca O, Simmaco M, Osti MF.

Radiat Oncol J. 2018 Sep;36(3):218-226. doi: 10.3857/roj.2018.00094. Epub 2018 Sep 30.

4.

Tryptophan and Kynurenine Metabolites: Are They Related to Depression?

Pompili M, Lionetto L, Curto M, Forte A, Erbuto D, Montebovi F, Seretti ME, Berardelli I, Serafini G, Innamorati M, Amore M, Baldessarini RJ, Girardi P, Simmaco M.

Neuropsychobiology. 2018 Aug 15:1-6. doi: 10.1159/000491604. [Epub ahead of print]

PMID:
30110684
5.

Psychopharmacological treatment of Obsessive-Compulsive Disorder (OCD).

Del Casale A, Sorice S, Padovano A, Simmaco M, Ferracuti S, Lamis DA, Rapinesi C, Sani G, Girardi P, Kotzalidis GD, Pompili M.

Curr Neuropharmacol. 2018 Aug 13. doi: 10.2174/1570159X16666180813155017. [Epub ahead of print]

PMID:
30101713
6.

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P.

J Transl Med. 2018 Aug 6;16(1):219. doi: 10.1186/s12967-018-1595-3.

7.

Changing the Approach to Anticoagulant Therapy in Older Patients with Multimorbidity Using a Precision Medicine Approach.

Koverech A, Soldati V, Polidori V, Pomes LM, Lionetto L, Capi M, Negro A, Simmaco M, Martelletti P.

Int J Environ Res Public Health. 2018 Aug 2;15(8). pii: E1634. doi: 10.3390/ijerph15081634.

8.

Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine.

Pomes LM, Gentile G, Simmaco M, Borro M, Martelletti P.

CNS Drugs. 2018 Jun 20. doi: 10.1007/s40263-018-0532-6. [Epub ahead of print] No abstract available.

PMID:
29926370
9.

Maternal exposure to endocrine disruptors and placental transmission: a pilot study.

Caserta D, Pegoraro S, Mallozzi M, Di Benedetto L, Colicino E, Lionetto L, Simmaco M.

Gynecol Endocrinol. 2018 May 29:1-4. doi: 10.1080/09513590.2018.1473362. [Epub ahead of print]

PMID:
29842821
10.

Short-term one-lung ventilation does not influence local inflammatory cytokine response after lung resection.

Fiorelli S, Defraia V, Cipolla F, Menna C, Ibrahim M, Andreetti C, Simmaco M, Rocco M, Rendina EA, Borro M, Massullo D.

J Thorac Dis. 2018 Mar;10(3):1864-1874. doi: 10.21037/jtd.2018.03.50.

11.

A transnational collaborative network dedicated to the study and applications of the vascular endothelial growth factor-A in medical practice: the VEGF Consortium.

Stathopoulou MG, Xie T, Ruggiero D, Chatelin J, Rancier M, Weryha G, Kurth MJ, Aldasoro Arguinano AA, Gorenjak V, Petrelis AM, Dagher G, Dedoussis G, Deloukas P, Lamont J, Marc J, Simmaco M, Schaik RHNV, Innocenti F, Merlin JL, Schneider J, Alizadeh BZ, Ciullo M, Seshadri S, Visvikis-Siest S; VEGF Consortium.

Clin Chem Lab Med. 2018 Mar 28;56(4):83-86. doi: 10.1515/cclm-2017-0838. No abstract available.

PMID:
29087954
12.

Genetic association analysis of serotonin and signal transduction pathways in suicide attempters from an Italian sample of psychiatric patients.

Pompili M, Gentile G, Scassellati C, Bonvicini C, Innamorati M, Erbuto D, Montebovi F, Ducci G, Forte A, De Pisa E, Ferracuti S, Serafini G, De Luca V, Amore M, Simmaco M, Girardi P.

Neurosci Lett. 2017 Aug 24;656:94-102. doi: 10.1016/j.neulet.2017.07.020. Epub 2017 Jul 14.

PMID:
28716530
13.

Stable Remission of Multiple Chemical Sensitivity Syndrome and Major Depression With Citalopram and 1-Month Deep Transcranial Magnetic Stimulation: A Case Report.

Del Casale A, Rapinesi C, Kotzalidis GD, Sorice S, Padovano A, Gentile G, Angeletti G, Ferracuti S, Sani G, Pompili M, Simmaco M, Girardi P.

J ECT. 2017 Sep;33(3):e27-e29. doi: 10.1097/YCT.0000000000000420. No abstract available.

PMID:
28570499
14.

Changes in serum levels of kynurenine metabolites in paediatric patients affected by ADHD.

Evangelisti M, De Rossi P, Rabasco J, Donfrancesco R, Lionetto L, Capi M, Sani G, Simmaco M, Nicoletti F, Villa MP.

Eur Child Adolesc Psychiatry. 2017 Dec;26(12):1433-1441. doi: 10.1007/s00787-017-1002-2. Epub 2017 May 19.

PMID:
28527020
15.

Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension?

Fazio F, Carrizzo A, Lionetto L, Damato A, Capocci L, Ambrosio M, Battaglia G, Bruno V, Madonna M, Simmaco M, Nicoletti F, Vecchione C.

Front Pharmacol. 2017 May 1;8:214. doi: 10.3389/fphar.2017.00214. eCollection 2017.

16.

Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.

Angelini S, Botticelli A, Onesti CE, Giusti R, Sini V, Durante V, Strigari L, Gentile G, Cerbelli B, Pellegrini P, Sgroi V, Occhipinti M, DI Pietro FR, Rossi A, Simmaco M, Mazzuca F, Marchetti P.

Anticancer Res. 2017 May;37(5):2633-2639.

PMID:
28476838
17.

A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.

Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F.

Anticancer Drugs. 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492.

PMID:
28296649
18.

Clinical Applications of Personalized Medicine: A New Paradigm and Challenge.

Di Sanzo M, Cipolloni L, Borro M, La Russa R, Santurro A, Scopetti M, Simmaco M, Frati P.

Curr Pharm Biotechnol. 2017;18(3):194-203. doi: 10.2174/1389201018666170224105600. Review.

PMID:
28240172
19.

LC-MS/MS simultaneous analysis of allopregnanolone, epiallopregnanolone, pregnanolone, dehydroepiandrosterone and dehydroepiandrosterone 3-sulfate in human plasma.

Lionetto L, De Andrés F, Capi M, Curto M, Sabato D, Simmaco M, Bossù P, Sacchinelli E, Orfei MD, Piras F, Banaj N, Spalletta G.

Bioanalysis. 2017 Mar;9(6):527-539. doi: 10.4155/bio-2016-0262. Epub 2017 Feb 16.

PMID:
28207286
20.

Personalised Healthcare: The DiMA Clinical Model.

Borro M, Gentile G, Cipolloni L, Foldes-Papp Z, Frati P, Santurro A, Lionetto L, Simmaco M.

Curr Pharm Biotechnol. 2017;18(3):242-252. doi: 10.2174/1389201018666170208125131. Review.

PMID:
28183244
21.

Personalized Medicine Applied to Forensic Sciences: New Advances and Perspectives for a Tailored Forensic Approach.

Santurro A, Vullo AM, Borro M, Gentile G, La Russa R, Simmaco M, Frati P, Fineschi V.

Curr Pharm Biotechnol. 2017;18(3):263-273. doi: 10.2174/1389201018666170207141525. Review.

PMID:
28176637
22.

Integrated OMICS tools for personalised medicine.

Borro M, Gentile G, Lionetto L, Simmaco M.

J Headache Pain. 2015 Dec;16(Suppl 1):A9. doi: 10.1186/1129-2377-16-S1-A9. No abstract available.

23.

The metabolite beta-aminoisobutyric acid and physical inactivity among hemodialysis patients.

Molfino A, Amabile MI, Ammann T, Farcomeni A, Lionetto L, Simmaco M, Lai S, Laviano A, Rossi Fanelli F, Chiappini MG, Muscaritoli M.

Nutrition. 2017 Feb;34:101-107. doi: 10.1016/j.nut.2016.07.012. Epub 2016 Jul 30.

PMID:
28063504
24.

Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.

Roberto M, Romiti A, Botticelli A, Mazzuca F, Lionetto L, Gentile G, Paris I, Falcone R, Bassanelli M, Di Pietro FR, Onesti CE, Anselmi E, Macrini S, Simmaco M, Marchetti P.

Eur J Clin Pharmacol. 2017 Feb;73(2):157-164. doi: 10.1007/s00228-016-2160-8. Epub 2016 Nov 18.

PMID:
27864592
25.

5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.

Onesti CE, Botticelli A, La Torre M, Borro M, Gentile G, Romiti A, Lionetto L, Petremolo A, Occhipinti M, Roberto M, Falcone R, Simmaco M, Marchetti P, Mazzuca F.

Anticancer Drugs. 2017 Mar;28(3):322-326. doi: 10.1097/CAD.0000000000000453.

PMID:
27845948
26.

Hedonic sensitivity to natural rewards is affected by prenatal stress in a sex-dependent manner.

Reynaert ML, Marrocco J, Mairesse J, Lionetto L, Simmaco M, Deruyter L, Allorge D, Moles A, Pittaluga A, Maccari S, Morley-Fletcher S, Van Camp G, Nicoletti F.

Addict Biol. 2016 Nov;21(6):1072-1085. doi: 10.1111/adb.12270. Epub 2015 May 26.

PMID:
26011513
27.

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.

Borro M, Botticelli A, Mazzuca F, Onesti EC, Gentile G, Romiti A, Cerbelli B, Mazzotti E, Marchetti L, Lionetto L, Simmaco M, Marchetti P.

Oncotarget. 2017 Feb 21;8(8):14050-14057. doi: 10.18632/oncotarget.12571.

28.

Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?

Botticelli A, Borro M, Onesti CE, Strigari L, Gentile G, Cerbelli B, Romiti A, Occhipinti M, Sebastiani C, Lionetto L, Marchetti L, Simmaco M, Marchetti P, Mazzuca F.

PLoS One. 2016 Sep 22;11(9):e0163105. doi: 10.1371/journal.pone.0163105. eCollection 2016.

29.

The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.

Romiti A, Roberto M, D'Antonio C, Onesti CE, Barucca V, Milano A, Gentile G, Lionetto L, Medda E, Mazzuca F, Botticelli A, Falcone R, Simmaco M, Marchetti P.

Anticancer Drugs. 2016 Nov;27(10):1044-9. doi: 10.1097/CAD.0000000000000429.

PMID:
27557140
30.

Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study.

Buscarinu MC, Cerasoli B, Annibali V, Policano C, Lionetto L, Capi M, Mechelli R, Romano S, Fornasiero A, Mattei G, Piras E, Angelini DF, Battistini L, Simmaco M, Umeton R, Salvetti M, Ristori G.

Mult Scler. 2017 Mar;23(3):442-446. doi: 10.1177/1352458516652498. Epub 2016 Jul 11.

PMID:
27270497
31.

H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine.

Borro M, Simmaco M, Aceti A, Barni S, De Luca A, Fineschi V, Frati P, Girardi P, Miozzo M, Nati G, Nicoletti F, Santini D, Marchetti P.

Curr Pharm Biotechnol. 2016;17(10):926-9.

PMID:
27194357
32.

Altered kynurenine pathway metabolites in serum of chronic migraine patients.

Curto M, Lionetto L, Negro A, Capi M, Fazio F, Giamberardino MA, Simmaco M, Nicoletti F, Martelletti P.

J Headache Pain. 2015;17:47. doi: 10.1186/s10194-016-0638-5. Epub 2016 Apr 29.

33.

CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.

Mazzuca F, Botticelli A, Mazzotti E, La Torre M, Borro M, Marchetti L, Maddalena C, Gentile G, Simmaco M, Marchetti P.

Eurasian J Med. 2016 Feb;48(1):10-4. doi: 10.5152/eurasianjmed.2015.008. Epub 2015 Jul 7.

34.

Altered serum levels of kynurenine metabolites in patients affected by cluster headache.

Curto M, Lionetto L, Negro A, Capi M, Perugino F, Fazio F, Giamberardino MA, Simmaco M, Nicoletti F, Martelletti P.

J Headache Pain. 2015;17:27. doi: 10.1186/s10194-016-0620-2. Epub 2016 Mar 22.

35.

Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.

Mazzuca F, Borro M, Botticelli A, Mazzotti E, Marchetti L, Gentile G, La Torre M, Lionetto L, Simmaco M, Marchetti P.

Oncotarget. 2016 Apr 12;7(15):20612-20. doi: 10.18632/oncotarget.7991.

36.

Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia.

Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, Ulivieri M, Napoletano F, Capi M, Corigliano V, Scaccianoce S, Caruso A, Miele J, De Fusco A, Di Menna L, Comparelli A, De Carolis A, Gradini R, Nisticò R, De Blasi A, Girardi P, Bruno V, Battaglia G, Nicoletti F, Simmaco M.

Sci Rep. 2015 Dec 8;5:17799. doi: 10.1038/srep17799.

37.

FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

Botticelli A, Mazzuca F, Borro M, Mazzotti E, La Torre M, Bonifacino A, Ciabatta FR, Gentile G, Maddalena C, Simmaco M, Marchetti P.

World J Oncol. 2015 Oct;6(5):437-440. doi: 10.14740/wjon934w. Epub 2015 Oct 26.

38.

Systems medicine, personalized health and therapy.

Siest G, Auffray C, Taniguchi N, Ingelman-Sundberg M, Murray H, Visvikis-Siest S, Ansari M, Marc J, Jacobs P, Meyer U, Van Schaik RH, Müller MM, Wevers RA, Simmaco M, Kussmann M, Manolopoulos VG, Alizadeh BZ, Beastall G, Németh G.

Pharmacogenomics. 2015;16(14):1527-39. doi: 10.2217/pgs.15.103. Epub 2015 Sep 24.

PMID:
26401575
39.

Personalized Cancer Therapy Considering Cytochrome P450 Variability.

Preissner S, Simmaco M, Gentile G, Preissner R.

Adv Pharmacol. 2015;74:113-30. doi: 10.1016/bs.apha.2015.03.004. Epub 2015 May 11. Review.

PMID:
26233905
40.

Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy.

Mazzuca F, Borro M, Botticelli A, Aimati L, Gentile G, Capalbo C, Maddalena C, Mazzotti E, Simmaco M, Marchetti P.

World J Oncol. 2015 Aug;6(4):394-397. doi: 10.14740/wjon930w. Epub 2015 Aug 27.

41.

Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.

Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P, Borro M.

Pharmacogenomics J. 2016 Aug;16(4):320-5. doi: 10.1038/tpj.2015.56. Epub 2015 Jul 28.

PMID:
26216193
42.

Intestinal permeability in children with recurrent respiratory and gastrointestinal symptoms.

Barreto M, Evangelisti M, Principessa L, Simmaco M, Negro V, Lionetto L, Campisano M, Villa MP.

J Paediatr Child Health. 2015 Dec;51(12):1214-20. doi: 10.1111/jpc.12927. Epub 2015 Jun 4.

PMID:
26044914
43.

Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.

Osti MF, Nicosia L, Agolli L, Gentile G, Falco T, Bracci S, Di Nardo F, Minniti G, De Sanctis V, Valeriani M, Maglio M, Borro M, Simmaco M, Enrici RM.

Am J Clin Oncol. 2017 Dec;40(6):535-542. doi: 10.1097/COC.0000000000000182.

PMID:
25811296
44.

Mitochondrial myopathy and comorbid major depressive disorder: effectiveness of dTMS on gait and mood symptoms.

Rapinesi C, Janiri D, Kotzalidis GD, Serata D, Del Casale A, Scatena P, Dacquino C, Gentile G, Manfredi G, Danese E, Raccah RN, Brugnoli R, Callovini G, Ferri VR, Ferracuti S, Zangen A, Simmaco M, Angeletti G, Girardi P.

Gen Hosp Psychiatry. 2015 May-Jun;37(3):274.e7-9. doi: 10.1016/j.genhosppsych.2015.03.002. Epub 2015 Mar 13.

PMID:
25799088
45.

Single nucleotide polymorphisms related to vitamin B12 serum levels in autoimmune gastritis patients with or without pernicious anaemia.

Lahner E, Gentile G, Purchiaroni F, Mora B, Simmaco M, Annibale B.

Dig Liver Dis. 2015 Apr;47(4):285-90. doi: 10.1016/j.dld.2015.01.147. Epub 2015 Jan 22.

PMID:
25681243
46.

Lack of association between oxidative stress-related gene polymorphisms and chronic migraine in an Italian population.

Gentile G, Negro A, D'Alonzo L, Aimati L, Simmaco M, Martelletti P, Borro M.

Expert Rev Neurother. 2015 Feb;15(2):215-25. doi: 10.1586/14737175.2015.1001748. Epub 2015 Jan 14.

PMID:
25585507
47.

Vitamin D receptor ApaI a allele is associated with better childhood asthma control and improvement in ability for daily activities.

Iordanidou M, Paraskakis E, Giannakopoulou E, Tavridou A, Gentile G, Borro M, Simmaco M, Chatzimichael A, Bush A, Manolopoulos VG.

OMICS. 2014 Nov;18(11):673-81. doi: 10.1089/omi.2014.0023. Epub 2014 Oct 29.

PMID:
25353337
48.

Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740.

Orlando R, Borro M, Motolese M, Molinaro G, Scaccianoce S, Caruso A, di Nuzzo L, Caraci F, Matrisciano F, Pittaluga A, Mairesse J, Simmaco M, Nisticò R, Monn JA, Nicoletti F.

Neuropharmacology. 2014 Nov;86:133-44. doi: 10.1016/j.neuropharm.2014.07.009. Epub 2014 Jul 22.

PMID:
25063582
49.

Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats.

D'Amore V, Santolini I, Celli R, Lionetto L, De Fusco A, Simmaco M, van Rijn CM, Vieira E, Stauffer SR, Conn PJ, Bosco P, Nicoletti F, van Luijtelaar G, Ngomba RT.

Neuropharmacology. 2014 Oct;85:91-103. doi: 10.1016/j.neuropharm.2014.05.005. Epub 2014 May 20.

50.

Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice.

Fazio F, Zappulla C, Notartomaso S, Busceti C, Bessede A, Scarselli P, Vacca C, Gargaro M, Volpi C, Allegrucci M, Lionetto L, Simmaco M, Belladonna ML, Nicoletti F, Fallarino F.

Neuropharmacology. 2014 Jun;81:237-43. doi: 10.1016/j.neuropharm.2014.02.011. Epub 2014 Feb 21.

PMID:
24565643

Supplemental Content

Loading ...
Support Center